Suppr超能文献

儿童肿瘤协作组报告:局部尤因肉瘤局部复发高风险患者的识别

Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group.

作者信息

Ahmed Safia K, Randall R Lor, DuBois Steven G, Harmsen William S, Krailo Mark, Marcus Karen J, Janeway Katherine A, Geller David S, Sorger Joel I, Womer Richard B, Granowetter Linda, Grier Holcombe E, Gorlick Richard G, Laack Nadia N I

机构信息

Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.

Department of Orthopedics, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah.

出版信息

Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1286-1294. doi: 10.1016/j.ijrobp.2017.08.020. Epub 2017 Aug 24.

Abstract

PURPOSE

To identify clinical and treatment variables associated with a higher risk of local failure in Ewing sarcoma patients treated on recent Children's Oncology Group protocols.

METHODS AND MATERIALS

Data for 956 patients treated with ifosfamide and etoposide-based chemotherapy on INT-0091, INT-0154, and AEWS0031 were analyzed. Local treatment modalities were defined as surgery, definitive radiation therapy (RT), or surgery plus radiation (S+RT). Five-year cumulative incidence of local failure was determined.

RESULTS

The local failure rate for the entire cohort was 7.3%, with a 3.9% rate for surgery, 15.3% for RT (P<.01), and 6.6% for S+RT (P=.12). The local failure incidence was 5.4% for extremity tumors, 13.2% for pelvis tumors (P<.01), 5.3% for axial non-spine tumors (P=.90), 9.1% for extraskeletal tumors (P=.08), and 3.6% for spine tumors (P=.49). The incidence of local failure was 14.8% for extremity tumors and 22.4% for pelvis tumors treated with RT, compared with 3.7% for extremity tumors and 3.9% for pelvis tumors treated with surgery (P≤.01). There was no difference in local failure incidence by local treatment modality for axial non-spine, spine, and extraskeletal tumors. The local failure incidence was 11.9% in patients aged ≥18 years versus 6.7% in patients aged <18 years (P=.02). Age ≥18 years (hazard ratio 1.9, P=.04) and treatment with RT (hazard ratio 2.40, P<.01) remained independent prognostic factors for higher local failure incidence on multivariate analysis. Tumor size (</≥ 8 cm) was available in 40% of patients and did not correlate with local failure incidence.

CONCLUSIONS

Local tumor control is excellent and similar between surgery and RT for axial non-spine, spine, and extraskeletal tumors. Age ≥18 years and use of RT, primarily for pelvis and extremity tumors, are associated with the highest risk of local failure. Further efforts should focus on improving outcomes for these patients.

摘要

目的

确定在儿童肿瘤学组近期方案治疗的尤因肉瘤患者中,与局部复发高风险相关的临床和治疗变量。

方法和材料

分析了956例接受基于异环磷酰胺和依托泊苷化疗的INT-0091、INT-0154和AEWS0031方案治疗患者的数据。局部治疗方式定义为手术、根治性放疗(RT)或手术加放疗(S+RT)。确定了局部复发的5年累积发生率。

结果

整个队列的局部复发率为7.3%,手术组为3.9%,放疗组为15.3%(P<0.01),手术加放疗组为6.6%(P=0.12)。肢体肿瘤的局部复发发生率为5.4%,骨盆肿瘤为13.2%(P<0.01),轴位非脊柱肿瘤为5.3%(P=0.90),骨外肿瘤为9.1%(P=0.08),脊柱肿瘤为3.6%(P=0.49)。接受放疗的肢体肿瘤和骨盆肿瘤的局部复发发生率分别为14.8%和22.4%,而接受手术治疗的肢体肿瘤和骨盆肿瘤分别为3.7%和3.9%(P≤0.01)。轴位非脊柱、脊柱和骨外肿瘤的局部治疗方式在局部复发发生率上无差异。≥18岁患者的局部复发发生率为11.9%,<18岁患者为6.7%(P=0.02)。多因素分析显示,≥18岁(风险比1.9,P=0.04)和放疗(风险比2.40,P<0.01)仍然是局部复发发生率较高的独立预后因素。40%的患者有肿瘤大小(</≥8 cm)数据,其与局部复发发生率无关。

结论

对于轴位非脊柱、脊柱和骨外肿瘤,手术和放疗的局部肿瘤控制效果良好且相似。≥18岁以及主要针对骨盆和肢体肿瘤使用放疗与局部复发的最高风险相关。应进一步努力改善这些患者的治疗结果。

相似文献

1
Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group.
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1286-1294. doi: 10.1016/j.ijrobp.2017.08.020. Epub 2017 Aug 24.
2
Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group.
J Clin Oncol. 2006 Aug 20;24(24):3838-43. doi: 10.1200/JCO.2006.05.9188.
5
Prognostic factors for local and distant control in Ewing sarcoma family of tumors.
Ann Oncol. 2008 Apr;19(4):814-20. doi: 10.1093/annonc/mdm521. Epub 2007 Nov 12.
6
Local Control Modality and Outcome for Ewing Sarcoma of the Femur: A Report From the Children's Oncology Group.
Ann Surg Oncol. 2016 Oct;23(11):3541-3547. doi: 10.1245/s10434-016-5269-1. Epub 2016 May 23.
7
Extraskeletal Ewing's sarcoma family of tumors in adults: prognostic factors and clinical outcome.
Jpn J Clin Oncol. 2012 May;42(5):420-6. doi: 10.1093/jjco/hys027. Epub 2012 Mar 12.
8
Pelvis Ewing sarcoma: Local control and survival in the modern era.
Pediatr Blood Cancer. 2017 Sep;64(9). doi: 10.1002/pbc.26504. Epub 2017 Feb 28.
10
The role of radiotherapy in local control of nonextremity Ewing sarcomas.
Tumori. 2016 Mar-Apr;102(2):162-7. doi: 10.5301/tj.5000478. Epub 2016 Feb 19.

引用本文的文献

1
Definitive Radiation Therapy for Ewing Sarcoma: Outcomes Based on Tumor Volume, Dose, and Fractionation.
Adv Radiat Oncol. 2025 Jun 9;10(8):101820. doi: 10.1016/j.adro.2025.101820. eCollection 2025 Aug.
3
Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, and Other Round Cell Sarcomas.
Hematol Oncol Clin North Am. 2025 Aug;39(4):709-726. doi: 10.1016/j.hoc.2025.04.003. Epub 2025 May 14.
4
Comprehensive Analysis of Treatment Approaches in Chest Wall Ewing Sarcoma: The Impact of Tumor Volume on Oncologic Outcomes.
Adv Radiat Oncol. 2025 Feb 28;10(4):101729. doi: 10.1016/j.adro.2025.101729. eCollection 2025 Apr.
5
Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target.
Int J Mol Sci. 2025 Feb 25;26(5):1973. doi: 10.3390/ijms26051973.
6
The Combination of PARP and Topoisomerase 1 Inhibitors Improves Radiation Therapy for Ewing Sarcoma.
Cancer Sci. 2025 Jun;116(6):1703-1714. doi: 10.1111/cas.70042. Epub 2025 Mar 11.
7
Real world data of Ewing sarcoma from a resource-limited setting with poor compliance to treatment leading to poor outcomes.
Ecancermedicalscience. 2024 Nov 14;18:1801. doi: 10.3332/ecancer.2024.1801. eCollection 2024.
8
UK guidelines for the management of bone sarcomas.
Br J Cancer. 2025 Jan;132(1):32-48. doi: 10.1038/s41416-024-02868-4. Epub 2024 Nov 16.
9
Real-world experiences in patients with Ewing sarcoma treated at a specialist centre in Turkey.
J Bone Oncol. 2024 Jul 6;47:100619. doi: 10.1016/j.jbo.2024.100619. eCollection 2024 Aug.
10
Spatially Fractionated Radiation Therapy in Sarcomas: A Large Single-Institution Experience.
Adv Radiat Oncol. 2023 Nov 4;9(3):101401. doi: 10.1016/j.adro.2023.101401. eCollection 2024 Mar.

本文引用的文献

3
Pelvis Ewing sarcoma: Local control and survival in the modern era.
Pediatr Blood Cancer. 2017 Sep;64(9). doi: 10.1002/pbc.26504. Epub 2017 Feb 28.
4
Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival.
J Clin Oncol. 2016 Oct 20;34(30):3680-3685. doi: 10.1200/JCO.2016.68.1858.
5
Limited Margin Radiation Therapy for Children and Young Adults With Ewing Sarcoma Achieves High Rates of Local Tumor Control.
Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):119-26. doi: 10.1016/j.ijrobp.2016.04.001. Epub 2016 Apr 12.
7
A Prospective Outcomes Study of Proton Therapy for Chordomas and Chondrosarcomas of the Spine.
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):297-303. doi: 10.1016/j.ijrobp.2016.01.057.
8
Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome.
Radiology. 2016 Sep;280(3):905-15. doi: 10.1148/radiol.2016151301. Epub 2016 Mar 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验